HSBC initiated coverage of Repligen (RGEN) with a Buy rating and $150 price target While biotech funding and the regulatory environment are headwinds for the company, its volume leverage in a recovery is underappreciated, the analyst tells investors in a research note. The firm believes Repligen’s portfolio in bioprocessing can drive double-digit revenue growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN: